Background Despite anticoagulation, patients with atrial fibrillation (AF) experience persistent elevated cardiovascular risk ...

Abbott has announced the company has received approval from the U.S. Food and Drug Administration (FDA) for its Volt PFA ...

Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.

US FDA approves Abbott's Volt PFA System to treat patients with atrial fibrillation: Abbott Park, Illinois Wednesday, December 24, 2025, 12:00 Hrs [IST] Abbott, is a global health ...

Boston Scientific BSX has a stretched valuation, reflected in its Value Score of C. Shares of the company are trading at a forward five-year price/earnings (P/E) of 27.77X, above its median as well as ...

The US Food and Drug Administration (FDA) has granted approval for Abbott’s Volt PFA System, expanding treatment options for ...

Abbott will soon enter the competitive U.S. pulsed field ablation (PFA) market, having just received FDA approval for its ...

The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...

Abbott can now compete with Medtronic, Boston Scientific and J&J in the U.S. for the fast-growing pulsed field ablation ...

After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.

Abbott today announced the U.S. Food and Drug Administration (FDA) has approved the company's Volttm PFA System to treat patients battling atrial fibrillation (AFib). Abbott will soon begin commercial ...

Coffee and the caffeine in it were long-considered a risk for patients with certain heart conditions. But a recent study ...